ARS Pharmaceuticals, Inc. Q2 FY2024 Earnings Call

ARS Pharmaceuticals, Inc. (SPRY)

Earnings Call FY2024 Q2 Call date: 2024-08-09 Concluded

Quarter scorecard

Revenue

$500,000

+4900% YoY

Diluted EPS

$-0.13

Net income

-$12.52M

Revenue Under Collaboration Agreements $500,000

Revenue Under Supply Agreements $0

Product $0